Loading…

Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing

Aims To evaluate a novel atrial lead designed to reduce far-field sensing. Methods and results Sixty-three patients with standard pacing indications were randomized to receive an OptiSense™ 1699T (St Jude Medical, USA) or conventional pacing lead in the right atrium. Post-implant follow-up was condu...

Full description

Saved in:
Bibliographic Details
Published in:Europace (London, England) England), 2009-05, Vol.11 (5), p.618-624
Main Authors: Fung, Jeffrey W.H., Sperzel, Johannes, Yu, Cheuk Man, Chan, Joseph Y.S., Gelder, Robert N., Yang, Michael X., Rooke, Ryan, Boileau, Peter, Fröhlig, Gerd
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3
cites cdi_FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3
container_end_page 624
container_issue 5
container_start_page 618
container_title Europace (London, England)
container_volume 11
creator Fung, Jeffrey W.H.
Sperzel, Johannes
Yu, Cheuk Man
Chan, Joseph Y.S.
Gelder, Robert N.
Yang, Michael X.
Rooke, Ryan
Boileau, Peter
Fröhlig, Gerd
description Aims To evaluate a novel atrial lead designed to reduce far-field sensing. Methods and results Sixty-three patients with standard pacing indications were randomized to receive an OptiSense™ 1699T (St Jude Medical, USA) or conventional pacing lead in the right atrium. Post-implant follow-up was conducted for all patients at 90 days and for a subset at 360 days. Standard electrical parameters were measured. Thresholds of sensing were determined for far-field ventricular signals. The number of inappropriate mode switches was determined from the stored intracardiac electrogram (IEGM). At 90 days, an IEGM Holter recorded 24 h of IEGM. With atrial sensitivity programmed at 0.3 mV, no far-field sensing occurred in the OptiSense™ group, but it did occur in 20% and 30% of the control group at 90 and 360 days, respectively. Inappropriate mode switching was observed in 4% of the OptiSense™ group in contrast to 23% of the control group. The IEGM Holter found no far-field sensing in the OptiSense™ group, but did find 83 023 far-field events from 22% of control patients. The standard electrical parameters of the OptiSense™ leads were acceptable. Conclusion The OptiSense™ lead reduced ventricular far-field sensing in the atrium while maintaining satisfactory pacing and sensing performance, resulting in less inappropriate mode switch.
doi_str_mv 10.1093/europace/eup078
format article
fullrecord <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_proquest_miscellaneous_67178645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/europace/eup078</oup_id><sourcerecordid>67178645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7rp69iY5eRDq5mOzaY4ifsGKIHouaTJdI21ak9ZVf72Rrnj0NAPzvC_Dg9AxJeeUKD6HIbSdNpCWjsh8B02p4CxjRLHdtBOlMkGZmqCDGF8JIZIpsY8mVPElJ4JPkb4f6t4Z8D0EbGrnndE1ho8OggNvAG9c_4K1x7oPLl1q0BZbiG7tweK-xU2KNO4LcKVDVjmoLX7MNvodcAQfnV8for1K1xGOtnOGnq-vni5vs9XDzd3lxSoznJM-M8yUlVFWSQ75wuRUMEp0SRmxRkkQUhpWljJPb1sjmFGqJIQqwhYS5CIv-Qydjr1daN8GiH3RuGigrrWHdojFUlKZLxcigfMRNKGNMUBVdME1OnwWlBQ_Votfq8VoNSVOttVD2YD947caE3A2Au3Q_dv2DWd2hY8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67178645</pqid></control><display><type>article</type><title>Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing</title><source>Open Access: Oxford University Press Open Journals</source><creator>Fung, Jeffrey W.H. ; Sperzel, Johannes ; Yu, Cheuk Man ; Chan, Joseph Y.S. ; Gelder, Robert N. ; Yang, Michael X. ; Rooke, Ryan ; Boileau, Peter ; Fröhlig, Gerd</creator><creatorcontrib>Fung, Jeffrey W.H. ; Sperzel, Johannes ; Yu, Cheuk Man ; Chan, Joseph Y.S. ; Gelder, Robert N. ; Yang, Michael X. ; Rooke, Ryan ; Boileau, Peter ; Fröhlig, Gerd</creatorcontrib><description>Aims To evaluate a novel atrial lead designed to reduce far-field sensing. Methods and results Sixty-three patients with standard pacing indications were randomized to receive an OptiSense™ 1699T (St Jude Medical, USA) or conventional pacing lead in the right atrium. Post-implant follow-up was conducted for all patients at 90 days and for a subset at 360 days. Standard electrical parameters were measured. Thresholds of sensing were determined for far-field ventricular signals. The number of inappropriate mode switches was determined from the stored intracardiac electrogram (IEGM). At 90 days, an IEGM Holter recorded 24 h of IEGM. With atrial sensitivity programmed at 0.3 mV, no far-field sensing occurred in the OptiSense™ group, but it did occur in 20% and 30% of the control group at 90 and 360 days, respectively. Inappropriate mode switching was observed in 4% of the OptiSense™ group in contrast to 23% of the control group. The IEGM Holter found no far-field sensing in the OptiSense™ group, but did find 83 023 far-field events from 22% of control patients. The standard electrical parameters of the OptiSense™ leads were acceptable. Conclusion The OptiSense™ lead reduced ventricular far-field sensing in the atrium while maintaining satisfactory pacing and sensing performance, resulting in less inappropriate mode switch.</description><identifier>ISSN: 1099-5129</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/eup078</identifier><identifier>PMID: 19363053</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Aged ; Aged, 80 and over ; Atrial Fibrillation - physiopathology ; Atrial Fibrillation - therapy ; Electrocardiography ; Electrocardiography, Ambulatory ; Equipment Design ; Female ; Foreign-Body Migration ; Heart Atria - physiopathology ; Humans ; Male ; Middle Aged ; Pacemaker, Artificial - adverse effects ; Sensitivity and Specificity</subject><ispartof>Europace (London, England), 2009-05, Vol.11 (5), p.618-624</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3</citedby><cites>FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1604,27924,27925</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/europace/eup078$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19363053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fung, Jeffrey W.H.</creatorcontrib><creatorcontrib>Sperzel, Johannes</creatorcontrib><creatorcontrib>Yu, Cheuk Man</creatorcontrib><creatorcontrib>Chan, Joseph Y.S.</creatorcontrib><creatorcontrib>Gelder, Robert N.</creatorcontrib><creatorcontrib>Yang, Michael X.</creatorcontrib><creatorcontrib>Rooke, Ryan</creatorcontrib><creatorcontrib>Boileau, Peter</creatorcontrib><creatorcontrib>Fröhlig, Gerd</creatorcontrib><title>Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing</title><title>Europace (London, England)</title><addtitle>Europace</addtitle><description>Aims To evaluate a novel atrial lead designed to reduce far-field sensing. Methods and results Sixty-three patients with standard pacing indications were randomized to receive an OptiSense™ 1699T (St Jude Medical, USA) or conventional pacing lead in the right atrium. Post-implant follow-up was conducted for all patients at 90 days and for a subset at 360 days. Standard electrical parameters were measured. Thresholds of sensing were determined for far-field ventricular signals. The number of inappropriate mode switches was determined from the stored intracardiac electrogram (IEGM). At 90 days, an IEGM Holter recorded 24 h of IEGM. With atrial sensitivity programmed at 0.3 mV, no far-field sensing occurred in the OptiSense™ group, but it did occur in 20% and 30% of the control group at 90 and 360 days, respectively. Inappropriate mode switching was observed in 4% of the OptiSense™ group in contrast to 23% of the control group. The IEGM Holter found no far-field sensing in the OptiSense™ group, but did find 83 023 far-field events from 22% of control patients. The standard electrical parameters of the OptiSense™ leads were acceptable. Conclusion The OptiSense™ lead reduced ventricular far-field sensing in the atrium while maintaining satisfactory pacing and sensing performance, resulting in less inappropriate mode switch.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atrial Fibrillation - physiopathology</subject><subject>Atrial Fibrillation - therapy</subject><subject>Electrocardiography</subject><subject>Electrocardiography, Ambulatory</subject><subject>Equipment Design</subject><subject>Female</subject><subject>Foreign-Body Migration</subject><subject>Heart Atria - physiopathology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pacemaker, Artificial - adverse effects</subject><subject>Sensitivity and Specificity</subject><issn>1099-5129</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LxDAQhoMo7rp69iY5eRDq5mOzaY4ifsGKIHouaTJdI21ak9ZVf72Rrnj0NAPzvC_Dg9AxJeeUKD6HIbSdNpCWjsh8B02p4CxjRLHdtBOlMkGZmqCDGF8JIZIpsY8mVPElJ4JPkb4f6t4Z8D0EbGrnndE1ho8OggNvAG9c_4K1x7oPLl1q0BZbiG7tweK-xU2KNO4LcKVDVjmoLX7MNvodcAQfnV8for1K1xGOtnOGnq-vni5vs9XDzd3lxSoznJM-M8yUlVFWSQ75wuRUMEp0SRmxRkkQUhpWljJPb1sjmFGqJIQqwhYS5CIv-Qydjr1daN8GiH3RuGigrrWHdojFUlKZLxcigfMRNKGNMUBVdME1OnwWlBQ_Votfq8VoNSVOttVD2YD947caE3A2Au3Q_dv2DWd2hY8</recordid><startdate>200905</startdate><enddate>200905</enddate><creator>Fung, Jeffrey W.H.</creator><creator>Sperzel, Johannes</creator><creator>Yu, Cheuk Man</creator><creator>Chan, Joseph Y.S.</creator><creator>Gelder, Robert N.</creator><creator>Yang, Michael X.</creator><creator>Rooke, Ryan</creator><creator>Boileau, Peter</creator><creator>Fröhlig, Gerd</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200905</creationdate><title>Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing</title><author>Fung, Jeffrey W.H. ; Sperzel, Johannes ; Yu, Cheuk Man ; Chan, Joseph Y.S. ; Gelder, Robert N. ; Yang, Michael X. ; Rooke, Ryan ; Boileau, Peter ; Fröhlig, Gerd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atrial Fibrillation - physiopathology</topic><topic>Atrial Fibrillation - therapy</topic><topic>Electrocardiography</topic><topic>Electrocardiography, Ambulatory</topic><topic>Equipment Design</topic><topic>Female</topic><topic>Foreign-Body Migration</topic><topic>Heart Atria - physiopathology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pacemaker, Artificial - adverse effects</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fung, Jeffrey W.H.</creatorcontrib><creatorcontrib>Sperzel, Johannes</creatorcontrib><creatorcontrib>Yu, Cheuk Man</creatorcontrib><creatorcontrib>Chan, Joseph Y.S.</creatorcontrib><creatorcontrib>Gelder, Robert N.</creatorcontrib><creatorcontrib>Yang, Michael X.</creatorcontrib><creatorcontrib>Rooke, Ryan</creatorcontrib><creatorcontrib>Boileau, Peter</creatorcontrib><creatorcontrib>Fröhlig, Gerd</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Fung, Jeffrey W.H.</au><au>Sperzel, Johannes</au><au>Yu, Cheuk Man</au><au>Chan, Joseph Y.S.</au><au>Gelder, Robert N.</au><au>Yang, Michael X.</au><au>Rooke, Ryan</au><au>Boileau, Peter</au><au>Fröhlig, Gerd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing</atitle><jtitle>Europace (London, England)</jtitle><addtitle>Europace</addtitle><date>2009-05</date><risdate>2009</risdate><volume>11</volume><issue>5</issue><spage>618</spage><epage>624</epage><pages>618-624</pages><issn>1099-5129</issn><eissn>1532-2092</eissn><abstract>Aims To evaluate a novel atrial lead designed to reduce far-field sensing. Methods and results Sixty-three patients with standard pacing indications were randomized to receive an OptiSense™ 1699T (St Jude Medical, USA) or conventional pacing lead in the right atrium. Post-implant follow-up was conducted for all patients at 90 days and for a subset at 360 days. Standard electrical parameters were measured. Thresholds of sensing were determined for far-field ventricular signals. The number of inappropriate mode switches was determined from the stored intracardiac electrogram (IEGM). At 90 days, an IEGM Holter recorded 24 h of IEGM. With atrial sensitivity programmed at 0.3 mV, no far-field sensing occurred in the OptiSense™ group, but it did occur in 20% and 30% of the control group at 90 and 360 days, respectively. Inappropriate mode switching was observed in 4% of the OptiSense™ group in contrast to 23% of the control group. The IEGM Holter found no far-field sensing in the OptiSense™ group, but did find 83 023 far-field events from 22% of control patients. The standard electrical parameters of the OptiSense™ leads were acceptable. Conclusion The OptiSense™ lead reduced ventricular far-field sensing in the atrium while maintaining satisfactory pacing and sensing performance, resulting in less inappropriate mode switch.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>19363053</pmid><doi>10.1093/europace/eup078</doi><tpages>7</tpages></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1099-5129
ispartof Europace (London, England), 2009-05, Vol.11 (5), p.618-624
issn 1099-5129
1532-2092
language eng
recordid cdi_proquest_miscellaneous_67178645
source Open Access: Oxford University Press Open Journals
subjects Aged
Aged, 80 and over
Atrial Fibrillation - physiopathology
Atrial Fibrillation - therapy
Electrocardiography
Electrocardiography, Ambulatory
Equipment Design
Female
Foreign-Body Migration
Heart Atria - physiopathology
Humans
Male
Middle Aged
Pacemaker, Artificial - adverse effects
Sensitivity and Specificity
title Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T02%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20clinical%20experience%20with%20an%20atrial%20lead%20designed%20to%20minimize%20far-field%20R-wave%20sensing&rft.jtitle=Europace%20(London,%20England)&rft.au=Fung,%20Jeffrey%20W.H.&rft.date=2009-05&rft.volume=11&rft.issue=5&rft.spage=618&rft.epage=624&rft.pages=618-624&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/eup078&rft_dat=%3Cproquest_TOX%3E67178645%3C/proquest_TOX%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c330t-c2cbfc9d973e84c815210ab120dc97e577c2bb78305dc52c99b00190247e748b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67178645&rft_id=info:pmid/19363053&rft_oup_id=10.1093/europace/eup078&rfr_iscdi=true